Why did Henry Schein (HSIC) stock move recently?

On 8/4/2026, Henry Schein moved +3.0% — Henry Schein reported Q2 results with an EPS beat and raised full-year 2026 sales and EPS guidance on strong internal sales momentum and first-half performance, driving the gain. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Henry Schein (HSIC) overvalued or fairly valued?

MarketChacha shows Henry Schein's valuation in context — a trailing P/E of about 27.6, a forward P/E of about 15.1, a price-to-book of about 3.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Henry Schein's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.71×) from reported figures — education, not a rating.

What is Henry Schein's revenue?

Henry Schein reported revenue of $13.2B for FY2025, with net profit of $398.0M, per official filings.

What is the share price of Henry Schein (HSIC)?

Henry Schein last traded at $90.39 (+2.1% on the day), as of 9/2/2026 — a delayed quote shown for education, not investment advice.

Henry Schein

HSIC · NYSE · Healthcare · United States

Snapshot

TickerHSIC

ExchangeNYSE

SectorHealthcare

IndustryMedical Distribution

CountryUnited States

CEOMr. Andrea Albertini

Employees25,000

HeadquartersMelville, United States

Websitewww.henryschein.com

Filings tracked17

About Henry Schein

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Who owns it

Insiders0.8%
Institutions99.2%
Public & other0.0%

784 institutional holders

Ownership breakdown from public market data.

Top holders

Kohlberg Kravis Roberts & Co. L.P.14.04%
FMR, LLC6.78%
Blackrock Inc.6.30%
Artisan Partners Limited Partnership5.80%
Vanguard Capital Management LLC5.69%
JPMORGAN CHASE & CO3.90%
State Street Corporation3.86%
Vanguard Portfolio Management LLC3.71%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.71×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend3.4% → 3.0%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 3% · PAT -2%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.6B · EPS 1.44

Est. earnings growth +7.2%

Next fiscal year

Rev $14.4B · EPS 6.00

Est. earnings growth +11.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$13.2B

Net margin

3.0%

ROE

12.3%

Revenue CAGR (2y)

+3.4%

Profit CAGR (2y)

-2.2%

EPS (FY2025)

3.27

Net profit (FY2025)

$398.0M

Ask MarketChacha about HSIC

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Henry Schein reported Q2 results with an EPS beat and raised full-year 2026 sales and EPS guidance on strong internal sales momentum and first-half performance, driving the gain.
source 1 ↗source 2 ↗source 3 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$13.2B	$398.0M	3.27	3.0%	12.3%
FY2024	$12.7B	$390.0M	3.05	3.1%	11.5%
FY2023	$12.3B	$416.0M	3.16	3.4%	11.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$3.5B	$94.0M	0.82	2.7%
2026Q1	$3.4B	$107.0M	0.92	3.2%
2025Q3	$3.3B	$101.0M	0.84	3.0%
2025Q2	$3.2B	$86.0M	0.70	2.7%
2025Q1	$3.2B	$110.0M	0.88	3.5%
2024Q3	$3.2B	$99.0M	0.78	3.1%
2024Q2	$3.1B	$104.0M	0.80	3.3%
2024Q1	$3.2B	$93.0M	0.72	2.9%
2023Q3	$3.2B	$137.0M	1.05	4.3%
2023Q2	$3.1B	$121.0M	0.91	4.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q — QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
SEC8/4/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/30/2026material
8-K — Shareholder vote results, Reg FD disclosure, Exhibits
SEC5/22/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q — QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
SEC5/5/2026
8-K — Results of operations, Exhibits
SEC2/24/2026material
10-K — THE 2025 ANNUAL 10-K REPORT
SEC2/24/2026
8-K — Executive/director change, Bylaw/charter change, Exhibits
SEC1/12/2026material

2025

8-K — Material agreement, Material financial obligation, Exhibits
SEC12/23/2025material
8-K — Executive/director change, Exhibits
SEC12/23/2025material
8-K — Material agreement
SEC12/9/2025material
8-K — Results of operations, Exhibits
SEC11/4/2025material
10-Q — HENRY SCHEIN 3Q 2025 10-Q
SEC11/4/2025
8-K — Executive/director change
SEC9/9/2025material
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q — HENRY SCHEIN 2Q 2025 10-Q
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.